5th International Congress on MPD & MDS

 
 
 

The 5th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes took place November 5-7, 2009, in Brooklyn, New York.

 

Pomalidomide treats anemia associated with myelofibrosis

Mark Fuerst Read Article
Published: 12/13/09

Bone marrow biopsy showing myelofibrosis
Bone marrow biopsy
showing myelofibrosis

The immunomodulatory drug (IMiD) pomalidomide works well in the treatment of anemia associated with myelofibrosis, according to Ayalew Tefferi, MD, of the Mayo Clinic in Rochester, Minnesota. In a phase 2 randomized, multicenter, double-blind, adaptive design study, Dr Tefferi evaluated the safety and therapeutic activity of pomalidomide. This drug has demonstrated significant activity in the treatment of refractory multiple myeloma and myelofibrosis. [Read Article]

Is there a rationale for iron chelation therapy in MDS?

Mark Fuerst Read Article
Published: 12/02/09

Bone marrow aspirate showing MDS
Bone marrow aspirate
showing MDS

Is there a rationale for chelation therapy in MDS patients? asked Eliezer Rachmilewitz, MD, of The Edith Wolfson Medical Center in Holon, Israel. He posed the question at the 5th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes held November 5-7, 2009. Patients with myelodysplastic syndromes (MDS), particularly those with refractory anemia (RA) and refractory anemia with excess of blasts (RARS) with relatively long survival, are dependent on red blood cell (RBC) transfusions. That makes them potentially vulnerable to organ damage and life-threatening iron deposition, mainly in the liver, heart, and endocrine glands. [Read Article]

JAK2 V617F can get lost in transformation from MPD to AML

Jen Smith Read Article
Published: 12/01/09

Anthony Green, PhD
Anthony Green, PhD

New research shows that patients with chronic myeloproliferative disorders (MPDs) that are positive for the JAK2 V617F mutation can transform to acute myeloid leukemia (AML) that is JAK2 wild type. However, researchers have yet to determine the exact mechanism by which this phenomenon occurs. Anthony Green, PhD, FRCP, FRCPath, of Cambridge Institute for Medical Research in the UK, presented this unpublished research at the 5th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes, which took place November 5-7. [Read Article]

Peg-IFN could become new standard therapy in MPD

Jen Smith Read Article
Published: 11/30/09

Updated results of the PVN-1 trial have researchers wondering if pegylated interferon alpha 2a (peg-IFN α2a) could replace standard therapy for myeloproliferative disorders (MPDs). Peg-IFN α2a elicited a hematologic response rate of 100% and a complete response rate of 91% at 1 year of follow up. The drug showed significant activity against the MPD clone, and only 8% of patients discontinued the drug due to side effects, which is superior to results typically seen with IFNs. [Read Article]

There is no science to support conventional practices in CML

Jen Smith Read Article
Published: 11/27/09

Hagop Kantarjian, MD
Hagop Kantarjian, MD

Conventional treatment of chronic myeloid leukemia (CML) is in need of serious revision, according to a speaker at the 5th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes. Hagop Kantarjian, MD, of M.D. Anderson Cancer Center in Texas, said there is a lack of scientific data to support many of the practices common in CML treatment. And in fact, there is evidence to suggest these practices are inappropriate. [Read Article]

Speaker recommends RAS mutation screening for CMML patients

Mark Fuerst Read Article
Published: 11/25/09

CMML cells
CMML cells

RAS mutations can have a negative impact on the course of chronic myelomonocytic leukemia (CMML), playing a role in the evolution of the disease from the dysplastic to proliferative stage. Because of this, all CMML patients should be screened by allele-specific polymerase chain reaction (PCR) to check whether they are harboring RAS mutations, said Francesco Onida, MD, of the University of Milan in Milan, Italy, at the 5th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes held November 5-7, 2009, in Brooklyn, NY.  [Read Article]

Agents target Achilles’ heel of current CML therapy

Jen Smith Read Article
Published: 11/24/09

Jorge Cortes, MD
Jorge Cortes, MD

There are several investigational agents that demonstrate the potential to revolutionize the treatment of chronic myeloid leukemia (CML), as they have the ability to target the Achilles’ heel of current therapies: the T315I mutation. Jorge Cortes, MD, of M.D. Anderson Cancer Center in Texas, described these agents in his presentation at the 5th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes, which took place November 5-7. [Read Article]

Instrument assesses patient-reported outcomes in myelofibrosis

Mark Fuerst Read Article
Published: 11/23/09

Bone marrow biopsy showing myelofibrosis
Bone marrow biopsy
showing myelofibrosis

A novel measurement of patient-reported symptoms may help assess response to therapy in primary myelofibrosis. The Myelofibrosis Symptom Assessment Form (MFSAF) is an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis, said Ruben Mesa, MD, of the Mayo Clinic in Rochester, Minnesota, at the 5th International Congress on Myeloproliferative Diseases (MPD) and Myelodysplastic Syndromes held November 5-7, 2009, in Brooklyn, NY. [Read Article]

Speaker says WHO doesn’t know MPDs

Jen Smith Read Article
Published: 11/19/09

Jerry Spivak, MD
Jerry Spivak, MD

A specialist claims the WHO incorrectly classifies chronic myeloproliferative disorders (MPDs) and promotes diagnostic criteria for these diseases that are inadequate. Jerry Spivak, MD, of Johns Hopkins’s Center for the Chronic Myeloproliferative Disorders, argued these points at the 5th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes, which took place November 5-7. And he supported his arguments with data from medical literature as well as his own experience as a clinician. [Read Article]

Can we improve imatinib therapy in CML?

Jen Smith Read Article
Published: 11/18/09

John Goldman, DM, FRCP
John Goldman, DM, FRCP

A study presented at the ASH Annual Meeting last year suggested the addition of pegylated interferon (peg-IFN) greatly improves imatinib therapy in chronic myeloid leukemia (CML). However, the latest data from that study indicates that may not be the case. Last year’s data from the SPIRIT trial showed that peg-IFN improved molecular responses in CML patients taking imatinib. But this year’s data show that the improved response does not translate to an improvement in patient survival. [Read Article]

Speaker proposes treatment algorithm for PMF

Mark Fuerst Read Article
Published: 11/17/09

Bone marrow biopsy showing myelofibrosis
Bone marrow biopsy
showing myelofibrosis

Due to its associated risks, allogeneic hematopoietic stem cell transplantation (HSCT) with either reduced-intensity conditioning or standard conditioning should be restricted to primary myelofibrosis (PMF) patients with high-risk or intermediate 2 risk disease or those who are resistant to conventional treatment, according to Francisco Cervantes, MD, of the Hospital Clinic at the University of Barcelona. He spoke at the 5th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes held recently in Brooklyn, New York, and proposed a treatment algorithm for PMF. [Read Article]

Is there a role for iron chelation in MDS?

Jen Smith Read Article
Published: 11/16/09

Gail Roboz, MD
Gail Roboz, MD

The role of chelation therapy in patients with myelodysplastic syndromes (MDS) has long been a subject of controversy. And it seems that, until researchers conduct prospective trials to examine the issue more closely, the controversy will continue. At least that was the point made by Gail Roboz, MD, of Weill Cornell Medical College, at the 5th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes. Dr Roboz said, at the moment, the topic of iron chelation in MDS raises more questions than answers. [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}